These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 1270131)

  • 21. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.
    Svennerholm AM; Jertborn M; Gothefors L; Karim AM; Sack DA; Holmgren J
    J Infect Dis; 1984 Jun; 149(6):884-93. PubMed ID: 6736680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
    Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
    Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Experimental research on cholera vaccines. Local immunity].
    Manakhilov RB; Genova IuG; Bogatinov VT; Kostova EF
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Oct; (10):59-62. PubMed ID: 3799104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitoxic immunity to cholera in dogs immunized orally with cholera toxin.
    Pierce NF; Cray WC; Engel PF
    Infect Immun; 1980 Feb; 27(2):632-7. PubMed ID: 7380543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The adjuvant effect of pertussis endotoxin protein in modulating the immune response to cholera toxoid in mice.
    Sultzer BM; Craig JP; Castagna R
    Dev Biol Stand; 1985; 61():225-32. PubMed ID: 2872108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.
    Apter FM; Michetti P; Winner LS; Mack JA; Mekalanos JJ; Neutra MR
    Infect Immun; 1993 Dec; 61(12):5279-85. PubMed ID: 8225601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulins in bile and serum of the rabbit associated with protection after Vibrio cholerae infection and vaccination.
    Rijpkema SG; Jansen WH; Gielen H; Guinée PA
    Microb Pathog; 1987 Nov; 3(5):365-75. PubMed ID: 2462153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective antitoxic cholera immunity in mice: influence of route and number of immunizations and mode of action of protective antibodies.
    Lange S; Holmgren J
    Acta Pathol Microbiol Scand C; 1978 Aug; 86C(4):145-52. PubMed ID: 696335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intestinal immunization with soluble bacterial antigens: the example of cholera toxoid.
    Pierce NF
    Ciba Found Symp; 1976; (42):129-47. PubMed ID: 1086763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.
    Jertborn M; Svennerholm AM; Holmgren J
    J Clin Microbiol; 1986 Aug; 24(2):203-9. PubMed ID: 3528211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the tissue receptors for Vibrio cholerae and Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoid.
    Holmgren J
    Infect Immun; 1973 Dec; 8(6):851-9. PubMed ID: 4206342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae.
    Attridge SR; Rowley D
    J Infect Dis; 1983 Nov; 148(5):931-9. PubMed ID: 6195273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.
    Liang W; Wang S; Yu F; Zhang L; Qi G; Liu Y; Gao S; Kan B
    Infect Immun; 2003 Oct; 71(10):5498-504. PubMed ID: 14500467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.
    Levine MM; Kaper JB; Black RE; Clements ML
    Microbiol Rev; 1983 Dec; 47(4):510-50. PubMed ID: 6363898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera.
    Osek J; Jonson G; Svennerholm AM; Holmgren J
    Infect Immun; 1994 Jul; 62(7):2901-7. PubMed ID: 7911787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flagella-induced immunity against experimental cholera in adult rabbits.
    Yancey RJ; Willis DL; Berry LJ
    Infect Immun; 1979 Jul; 25(1):220-8. PubMed ID: 478635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine.
    Pierce NF; Kaper JB; Mekalanos JJ; Cray WC; Richardson K
    Infect Immun; 1987 Feb; 55(2):477-81. PubMed ID: 3804447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.